fe3o4 astragalus polysaccharide core shell nanoparticles for iron deficiency anemia therapy and magnetic resonance imaging in vivo

Male Cell Survival Contrast Media FOS: Physical sciences 02 engineering and technology Kidney Cell Line Mice Drug Stability Polysaccharides Animals Humans Physics - Biological Physics Rats, Wistar Mice, Inbred ICR Anemia, Iron-Deficiency Astragalus Plant Physics - Medical Physics Magnetic Resonance Imaging Ferrosoferric Oxide Rats 3. Good health Liver Solubility Biological Physics (physics.bio-ph) Nanoparticles Medical Physics (physics.med-ph) 0210 nano-technology
DOI: 10.48550/arxiv.1806.10740 Publication Date: 2019-02-25
ABSTRACT
Fe3O4@astragalus polysaccharide core-shell nanoparticles (Fe3O4@APS NPs) were demonstrated to be an efficient therapeutic drug for treating iron deficiency anemia (IDA) in vivo. The Fe3O4@APS NPs have been synthesized using a two steps approach involving hydrothermal synthesis and subsequent esterification. Transmission electron microscopy (TEM) and Fourier transform infrared (FTIR) spectroscopy studies show that APS are attached on the surfaces of the highly monodisperse Fe3O4 NPs. Dynamic light scatting (DLS) and magnetic characterizations reveal that the Fe3O4@APS NPs have outstanding water solubility and stability. Cytotoxicity assessment using Hela cells and pathological tests in mice demonstrate their good biocompatibility and low toxicity. The IDA treatment in rats shows that they have efficient therapeutic effect, which is contributed to both the iron element supplement from Fe3O4 and the APS-stimulated hematopoietic cell generation. Moreover, the Fe3O4@APS NPs are superparamagnetic and thus able to be used for magnetic resonance imaging (MRI). This study has demonstrated the potential of nanocomposites involving purified natural products from Chinese herb medicine for biomedical applications.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES ()
CITATIONS ()
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....